At a glance
ClinicalIndex Comparison RecordN/ACompleted· 147 enrolled
Drug / intervention
ExAblate MRfFUS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic and Multiple Myeloma Bone Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation Therapy
In Brief
A clinical study evaluating ExAblate MRfFUS and Sham for Bone Metastases and Multiple Myeloma. Completed, enrolled 147 participants across 14 sites in 5 countries.
Detailed Summary
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Metastases, Multiple Myeloma
CountriesCanada, Israel, Italy, Russia, United States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedApr 2008
Primary CompletionSep 2012
TodayJul 2026
First PostedApr 11, 2008
Enrollment StartMar 1, 2008
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 18.2 years ago
Interventions
ExAblate MRfFUSdevice
MR guided focused ultrasound.
Shamdevice
sham comparator